- Home
- Products
- Customized FluoroAb™
- FGFR2
- Anti-FGFR2 MAb (Clone 16)-iFluor® 405 Succinimidyl Ester
Anti-FGFR2 MAb (Clone 16)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS2063)
- TARGET
- ANTIBODY
- DYE
- Name
- FGFR2
- Alternative Names
- Fibroblast Growth Factor Receptor 2; Keratinocyte Growth Factor Receptor; Bacteria-Expressed Kinase; EC 2.7.10.1; K-SAM; KGFR; BEK; Protein Tyrosine Kinase; Receptor Like 14; BEK Fibroblast Growth Factor Receptor; Craniofacial Dysostosis 1; Jackson-Weiss Syndrome; Pfeiffer Syndrome; Crouzon Syndrome; CD332 Antigen;
- Overview
- The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member is a high-affinity receptor for acidic, basic and or keratinocyte growth factor, depending on the isoform. Mutations in this gene are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. Multiple alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Jan 2009]
- Overview
- Anti-FGFR2 Antibody (Clone 16)
- Species Reactivity
- Human
- Name
- iFluor® 405 Succinimidyl Ester
- Color
- Blue
- Excitation⁄Emission (nm)
- 403/427
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for WJY0-LS2063. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-055 | Anti-FGFR2-sulfo-SMCC-DM1 ADC-5 | sulfo-SMCC (sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-l-carbox late) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-061 | Anti-FGFR2-sulfo-SMCC-DM1 ADC-11 | sulfo-SMCC (sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-l-carbox late) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-054 | Anti-FGFR2-sulfo-SMCC-DM1 ADC-4 | sulfo-SMCC (sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-l-carbox late) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-557 | Anti-FGFR2-MMAE ADC | MMAE (Monomethyl auristatin E) | |
| ADC-W-065 | Anti-FGFR2-sulfo-SMCC-DM1 ADC-15 | sulfo-SMCC (sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-l-carbox late) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-RSV MAb (Clone 5)-iFluor® 460 Succinimidyl Ester (CAT#: WJY0-LS9261)
- Anti-MET MAb (Clone 3)-iFluor® 555 Succinimidyl Ester (CAT#: WJY0-LS16776)
- Anti-EPCAM MAb (Clone 6)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS2137)
- Anti-MUC16 MAb (Clone 14)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS11774)
- Anti-CD2 MAb (Clone 17)-iFluor® 555 Succinimidyl Ester (CAT#: WJY0-LS16494)
- Anti-PRLR MAb (Clone 1)-iFluor® 460 Succinimidyl Ester (CAT#: WJY0-LS7940)
- Anti-CD44 MAb (Clone 1)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS14658)
- Anti-FOLR1 MAb (Clone 4)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS2089)
- Anti-TNFRSF10B MAb (Clone 11)-iFluor® 555 Succinimidyl Ester (CAT#: WJY0-LS16358)
- Anti-PMEL MAb (Clone 1)-iFluor® 555 Succinimidyl Ester (CAT#: WJY0-LS15820)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
